Methods and compositions for derepression of iap-inhibited caspase
CA 2467892 A1 · Owner: Ostresh, John M. · Inventors: Welsh, Kate; Pinilla, Clemencia; Nefzi, Adel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides isolated agents having a core peptide selected from the group consisting of Core peptides 5 through 39 and 42 through 55 wherein the , agent derepresses an IAP-inhibited caspase. Also provided is an isolated agent having a core structure selected from any of the structures shown in Figures 5, 9, 10, 14B, and 21-24 wherein said agent derepresses an IAP-inhibited caspase. The invention further provides a method of derepressing an IAPinhibited caspase. The method consists of contacting an IAP-inhibited caspase with an effective amount of an agent to derepress an IAP-inhibited caspase the agent having a core motif selected from the group consisting of a core peptide …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 21, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 21, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 21, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.